Focal Healthcare news
Targeted MRI-US fusion biopsy is an emerging technology with the potential to change the standard of care for diagnosis and treatment. It combines the accuracy of MRI with the real-time monitoring of ultrasound to detect more clinically significant cancer, while preventing unnecessary biopsies. Unlike standard systematic biopsy, fusion can track lesions over time with
Compared to standard systematic biopsies, MRI-targeted fusion biopsies improve the detection of clinically significant prostate cancer. Studies have shown MRI can be a cost-effective and accurate first-line diagnostic tool for the early detection of prostate cancer. If the MRI is negative, patients may avoid biopsy, whereas positive results provide an action plan for biopsy
The collaboration allows Focal Healthcare to develop a smart 3D ultrasound imaging platform for point of care use.
TORONTO, CANADA – Focal Healthcare, known globally as a leading innovator of image-guided prostate cancer technology, is diversifying their product line by developing an AI-based 3D ultrasound imaging platform. Focal Healthcare has licensed patents from the Centre for Imaging Technology Commercialization (CIMTE
Prostate cancer is the second most common and lethal cancer among men in the United States. In 2021, an estimated 250,000 men were diagnosed, with the majority over 65 years old. During the height of the pandemic, diagnosis and screening numbers plummeted, resulting in thousands of mis